EP0831874A4 - Gentherapie bei myocardischemie - Google Patents

Gentherapie bei myocardischemie

Info

Publication number
EP0831874A4
EP0831874A4 EP96921461A EP96921461A EP0831874A4 EP 0831874 A4 EP0831874 A4 EP 0831874A4 EP 96921461 A EP96921461 A EP 96921461A EP 96921461 A EP96921461 A EP 96921461A EP 0831874 A4 EP0831874 A4 EP 0831874A4
Authority
EP
European Patent Office
Prior art keywords
gene therapy
myocardial ischemia
ischemia
myocardial
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96921461A
Other languages
English (en)
French (fr)
Other versions
EP0831874A1 (de
Inventor
Frank J Giordano
Wolfgang H Dillmann
Ruben Mestril
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP0831874A1 publication Critical patent/EP0831874A1/de
Publication of EP0831874A4 publication Critical patent/EP0831874A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
EP96921461A 1995-06-07 1996-06-07 Gentherapie bei myocardischemie Withdrawn EP0831874A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US481122 1983-04-01
US48112295A 1995-06-07 1995-06-07
PCT/US1996/009858 WO1996040195A1 (en) 1995-06-07 1996-06-07 Gene therapy for myocardial ischemia

Publications (2)

Publication Number Publication Date
EP0831874A1 EP0831874A1 (de) 1998-04-01
EP0831874A4 true EP0831874A4 (de) 2002-03-06

Family

ID=23910695

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96921461A Withdrawn EP0831874A4 (de) 1995-06-07 1996-06-07 Gentherapie bei myocardischemie

Country Status (4)

Country Link
EP (1) EP0831874A4 (de)
AU (1) AU6268196A (de)
CA (1) CA2221710A1 (de)
WO (1) WO1996040195A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
EP2244740A1 (de) 2008-02-19 2010-11-03 Celladon Corporation Zusammensetzungen zur verbesserten aufnahme von virusvektoren in das myokard

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021195A1 (en) * 1993-03-15 1994-09-29 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346812A (en) * 1989-09-07 1994-09-13 The University Of Miami Teratogen assay
US5071962A (en) * 1990-05-31 1991-12-10 The United State Of America As Represented By The Department Of Health And Human Services Nucleotide, deduced amino acid sequence, isolation and purification of heat-shock chlamydial proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021195A1 (en) * 1993-03-15 1994-09-29 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
CARDIOVASCULAR RESEARCH, vol. 27, no. 8, 1993, pages 1421 - 1429, ISSN: 0008-6363 *
CIRCULATION, vol. 84, no. 1, 1991, pages 350 - 356, ISSN: 0009-7322 *
CIRCULATION, vol. 88, no. 3, 1993, pages 1264 - 1272, ISSN: 0009-7322 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1991, LIU G S ET AL: "PROTECTION AGAINST INFARCTION AFFORDED BY PRECONDITIONING IS MEDIATED BY A-1 ADENOSINE RECEPTORS IN RABBIT HEART", XP002178759, Database accession no. PREV199192072341 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1993, ANDRES JANUSZ ET AL: "Expression of heat shock proteins in the normal and stunned porcine myocardium.", XP002178762, Database accession no. PREV199396111570 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1993, HATTORI HIROTOMO ET AL: "A stress-inducible 40 kDa protein (hsp40): Purification by modified two-dimensional gel electrophoresis and co-localization with hsc70(p73) in heat-shocked HeLa cells.", XP002178764, Database accession no. PREV199396024271 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1993, MARBER MICHAEL S ET AL: "Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction.", XP002178763, Database accession no. PREV199396120526 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, MARBER MICHAEL S ET AL: "Overexpression of the Rat Inducible 70-kD Heat Stress Protein in a Transgenic Mouse Increases the Resistance of the Heart to Ischemic Injury.", XP002178761, Database accession no. PREV199598231290 *
DILLMANN WOLFGANG H ET AL: "Heat shock proteins and ischemic injury.", JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT, no. 19B, 1995, Keystone Symposium on Heat Shock;Santa Fe, New Mexico, USA; February 27-March 5, 1995, pages 190, XP002178758, ISSN: 0733-1959 *
GIORDANO FRANK ET AL: "Adenovirus mediated inducible heat shock protein 70 gene transfer protects against simulated ischemia in a muscle derived cell line.", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, no. SPEC. ISSUE, 1995, 44th Annual Scientific Session of the American College of Cardiology;New Orleans, Louisiana, USA; March 19-22, 1995, pages 324A, XP002178757, ISSN: 0735-1097 *
JCU (JOURNAL OF CLINICAL ULTRASOUND), vol. 21, no. 4, 1993, pages 629 - 638 *
JOURNAL OF CLINICAL INVESTIGATION, vol. 95, no. 4, 1995, pages 1446 - 1456, ISSN: 0021-9738 *
LEE K J ET AL: "MYOSIN LIGHT CHAIN-2 LUCIFERASE TRANSGENIC MICE REVEAL DISTINCT REGULATORY PROGRAMS FOR CARDIAC AND SKELETAL MUSCLE-SPECIFIC EXPRESSION OF A SINGLE CONTRACTILE PROTEIN GENE", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 267, no. 22, 1992, pages 15875 - 15885, XP002001050, ISSN: 0021-9258 *
See also references of WO9640195A1 *

Also Published As

Publication number Publication date
WO1996040195A1 (en) 1996-12-19
CA2221710A1 (en) 1996-12-19
AU6268196A (en) 1996-12-30
EP0831874A1 (de) 1998-04-01

Similar Documents

Publication Publication Date Title
ZA961587B (en) Gene transfer-mediated angiogenesis therapy
IL117309A0 (en) Gene transfer-mediated angiogenesis therapy
GB9622500D0 (en) Therapeutic gene
GB9520822D0 (en) Therapeutically active compounds
AU699706C (en) Improved vectors for gene therapy
PL326981A1 (en) Pharmaceutic preparations
GB9518220D0 (en) Checkpoint gene
GB9523703D0 (en) Enzyme prodrug thearapy
HRP960375B1 (en) Therapeutically active compounds
GB2322131B (en) Improved retroviral vectors for gene therapy
ZA959846B (en) Enzyme prodrug therapy
HUP9901438A3 (en) Therapeutic pyrimidine compounds
EP0831874A4 (de) Gentherapie bei myocardischemie
AU4941096A (en) Self-deleting vectors for gene therapy
EP1038957A4 (de) Gen tsa305
GB9310441D0 (en) Gene therapy
GB9724828D0 (en) Gene
GB9520433D0 (en) Gene therapy
GB9521711D0 (en) Gene therapy
GB2333527B (en) Therapeutic gene
GB9523714D0 (en) Enzyme prodrug therapy
GB9526028D0 (en) Promoting gene expression
GB9615797D0 (en) Gene expression
GB9525962D0 (en) Gene expression
GB9711579D0 (en) Therapeutic genes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971217

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE ES FR GB IT

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 15/86 A, 7A 61K 38/00 B, 7A 61M 31/00 B, 7A 61K 48/00 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020118

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): DE ES FR GB IT

17Q First examination report despatched

Effective date: 20021105

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030516